We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+0.88%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$20.5M
(-9.7%)
Cap. Flow
-$12.4M
Cap. Flow
% of AUM
-6.5%
Top 10 Holdings %
Top 10 Hldgs %
8%
Holding
450
New
8
Increased
100
Reduced
215
Closed
125
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brookfield Infrastructure
BIPC
|
+$1.03M |
| 2 |
OXLC
Oxford Lane Capital
OXLC
|
+$1,000K |
| 3 |
ECC
Eagle Point Credit Company
ECC
|
+$951K |
| 4 |
ORAN
Orange
ORAN
|
+$441K |
| 5 |
SNP
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
|
+$424K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek Logistics
DKL
|
+$2.13M |
| 2 |
Western Midstream Partners
WES
|
+$888K |
| 3 |
CNXM
CNX Midstream Partners LP
CNXM
|
+$744K |
| 4 |
OSB
Norbord Inc.
OSB
|
+$695K |
| 5 |
Marathon Petroleum
MPC
|
+$594K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.34% |
| 2 | Real Estate | 18.02% |
| 3 | Energy | 12.43% |
| 4 | Materials | 10.7% |
| 5 | Financials | 6.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
BioNTech
BNTX
$23.4B
| $441K | 0.23% |
6,363
-849
| -12% | -$60.9K |
|
|
TPTX
152
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $440K | 0.23% |
5,034
-694
| -12% | -$48.3K |
|
153
Agios Pharmaceuticals
AGIO
$2.14B
| $434K | 0.23% |
12,398
+1,044
| +9% | +$45.8K |
|
154
CRISPR Therapeutics
CRSP
$4.68B
| $431K | 0.23% |
5,155
-689
| -12% | -$61.1K |
|
|
KIO
155
KKR Income Opportunities Fund
KIO
$452M
| $430K | 0.23% |
31,779
-21,338
| -40% | -$283K |
|
156
Atara Biotherapeutics
ATRA
$70.4M
| $426K | 0.22% |
1,314
-180
| -12% | -$61.3K |
|
157
Goldman Sachs BDC
GSBD
$1,000M
| $425K | 0.22% |
28,237
-1,654
| -6% | -$25.9K |
|
158
BioMarin Pharmaceuticals
BMRN
$12B
| $421K | 0.22% |
5,529
+466
| +9% | +$47.1K |
|
159
Golub Capital BDC
GBDC
$3.38B
| $420K | 0.22% |
31,732
-13,144
| -29% | -$164K |
|
160
Xencor
XNCR
$1.48B
| $420K | 0.22% |
10,833
-1,492
| -12% | -$51.8K |
|
161
Zymeworks
ZYME
$1.66B
| $420K | 0.22% |
9,021
-1,227
| -12% | -$42.1K |
|
162
Ares Capital
ARCC
$13.7B
| $414K | 0.22% |
29,644
-2,935
| -9% | -$41.8K |
|
|
MRNS
163
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $414K | 0.22% |
32,237
-4,403
| -12% | -$38K |
|
164
Rigel Pharmaceuticals
RIGL
$712M
| $411K | 0.22% |
17,124
-2,334
| -12% | -$57.3K |
|
165
Arrowhead Research
ARWR
$12.1B
| $406K | 0.21% |
9,424
-1,281
| -12% | -$55.3K |
|
166
Omeros
OMER
$816M
| $404K | 0.21% |
39,936
+3,363
| +9% | +$43.3K |
|
167
BridgeBio Pharma
BBIO
$16.8B
| $403K | 0.21% |
10,753
-1,458
| -12% | -$45.9K |
|
168
Sixth Street Specialty
TSLX
$1.68B
| $403K | 0.21% |
23,406
-2,143
| -8% | -$36.7K |
|
|
EPZM
169
DELISTED
Epizyme, Inc
EPZM
| $402K | 0.21% |
33,686
+2,837
| +9% | +$38K |
|
170
Fate Therapeutics
FATE
$270M
| $401K | 0.21% |
10,028
-1,361
| -12% | -$47.5K |
|
171
TriplePoint Venture Growth BDC
TPVG
$185M
| $401K | 0.21% |
36,328
-42,204
| -54% | -$472K |
|
|
ITCI
172
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $393K | 0.21% |
15,303
-2,089
| -12% | -$47.7K |
|
|
AKRO
173
DELISTED
Akero Therapeutics
AKRO
| $391K | 0.21% |
12,686
-1,739
| -12% | -$60.8K |
|
174
Rocket Pharmaceuticals
RCKT
$343M
| $389K | 0.2% |
16,995
-2,315
| -12% | -$57K |
|
175
MacroGenics
MGNX
$245M
| $388K | 0.2% |
15,384
-2,100
| -12% | -$57.3K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q3 2020 Portfolio in Review
As of Q3 2020, Virtus ETF Advisers held 450 positions worth $191M, down 9.7% from $211M the previous quarter. Its ten largest holdings account for 8% of the portfolio.
Virtus ETF Advisers withdrew a net $12.4M in Q3 2020, closing 125 positions and reducing 215 holdings. Its most notable exit was CNX Midstream Partners LP, an estimated $744K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 34% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Virtus ETF Advisers opened a new position in Oxford Lane Capital worth $1.03M.
- Virtus ETF Advisers's largest Q3 2020 buy was Oxford Lane Capital: 46,671 shares worth $1.03M.
- Virtus ETF Advisers added most to Brookfield Infrastructure in Q3 2020, an estimated $1.03M increase.
- Virtus ETF Advisers's biggest Q3 2020 reduction was Delek Logistics, cutting an estimated $2.13M.
- Virtus ETF Advisers fully exited CNX Midstream Partners LP in Q3 2020, selling an estimated $744K.
- Virtus ETF Advisers's ten largest holdings make up 8% of its $191M portfolio in Q3 2020.
- Virtus ETF Advisers opened 8 new positions and closed 125 in Q3 2020.
- Virtus ETF Advisers's portfolio value fell 9.7% quarter-over-quarter to $191M.
Based on Virtus ETF Advisers's 13F filing for Q3 2020, filed 13 Nov 2020.